Pernix announced the launch of a new formulation of Zohydro ER (hydrocodone bitartrate extended-release capsules) with BeadTek, a new abuse-deterrent technology.

The new formulation included BeadTek, which is an indistinguishable mix of inactive beads, active immediate-release hydrocodone beads, and active extended-release hydrocodone beads. The inactive beads remain inert and dissolve independently of the active hydrocodone beads. The inactive beads are designed not to change the 12-hour release properties of the medication when taken as directed, but will immediately form a viscous gel when crushed and dissolved in liquids or solvents.

RELATED: Drop in Prescribing, Overdoses Seen After Abuse-Deterrent Opioid Introduced

Zohydro ER with BeadTek is a Schedule II opioid agonist indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment (eg, non-opioid analgesics or immediate-release opioids) are inadequate.

Zohydro ER capsules with BeadTek are available in 10mg, 15mg, 20mg, 30mg, 40mg, and 50mg strengths.

For more information visit